劉忠,博士,畢業(yè)于德國洪堡大學(xué),協(xié)和學(xué)者特聘教授,博士生導(dǎo)師。入選四川省學(xué)術(shù)和技術(shù)帶頭人,全國抗擊新冠肺炎疫情先進(jìn)個人等稱號。主要從事臨床輸血的安全和有效性研究,在感染性輸血安全、精準(zhǔn)輸血及血液保存方面有較深入的研究。先后發(fā)表論文200多篇,其中SCI收錄文章近百篇,期刊包括JAMA、ACSNano、Haematol等,單篇他引最高700余次,主編專著5本,專利10余項(xiàng),成果轉(zhuǎn)化3項(xiàng)。
研究方向
臨床輸血、血液安全、血液保存等
社會任職及榮譽(yù)
北京協(xié)和醫(yī)學(xué)院輸血醫(yī)學(xué)系執(zhí)行主任、中國醫(yī)學(xué)科學(xué)院輸血不良反應(yīng)研究重點(diǎn)實(shí)驗(yàn)室主任、中國醫(yī)學(xué)科學(xué)院輸血研究所副所長、中華預(yù)防醫(yī)學(xué)會血液安全專業(yè)委員會主任委員、四川省輸血協(xié)會理事長、《中國輸血雜志》主編。第41屆國際低溫醫(yī)學(xué)、生物學(xué)大會(CRYO2004)秘書長,第49屆國際低溫生物學(xué)大會(CRYO2017)副主席等。獲省部級科技進(jìn)步獎5項(xiàng)。
承擔(dān)科研項(xiàng)目
- 中國醫(yī)學(xué)科學(xué)院新冠科技攻關(guān)項(xiàng)目恢復(fù)期血漿治療新冠肺炎臨床應(yīng)用研究2020
- 國際血液管理模式的研究,國家衛(wèi)生健康委醫(yī)政醫(yī)管局委托項(xiàng)目2018-2019
- 中國醫(yī)學(xué)科學(xué)院輸血不良反應(yīng)重點(diǎn)實(shí)驗(yàn)室,中國醫(yī)學(xué)科學(xué)院2017-2020
- 醫(yī)學(xué)健康與創(chuàng)新工程,《輸血不良反應(yīng)發(fā)生機(jī)制與干預(yù)》, 2016-2020
- 科技部科研院所技術(shù)開發(fā)項(xiàng)目,《我國輸血傳播病原體核酸檢測關(guān)鍵技術(shù)研究》,2014-2017
- 國家自然科學(xué)基金面上項(xiàng)目,《凍干紅細(xì)胞殘余水的性質(zhì)及其應(yīng)用研究》,2013-2017
- 國家衛(wèi)生和計(jì)劃生育委員會醫(yī)政醫(yī)管局委托項(xiàng)目《血液篩查策略與血液安全》,2016
- 國家衛(wèi)生和計(jì)劃生育委員會法制司委托項(xiàng)目《全血和成份血使用》衛(wèi)生標(biāo)準(zhǔn)制定2015-2016
- 國家衛(wèi)生和計(jì)劃生育委員會法制司委托項(xiàng)目《全血和成份血制備》衛(wèi)生標(biāo)準(zhǔn)制定2019-2022
- 國家衛(wèi)生計(jì)生委醫(yī)政醫(yī)管局委托項(xiàng)目,《獻(xiàn)血法》修訂草案研究,2015-2016
- 國家衛(wèi)生計(jì)生委醫(yī)政醫(yī)管局委托項(xiàng)目《初篩反應(yīng)陽性獻(xiàn)血者確證與召回策略研究》,2013-2016
- 國家衛(wèi)生計(jì)生委醫(yī)政醫(yī)管局委托項(xiàng)目《輸血傳播疾病保險(xiǎn)分擔(dān)機(jī)制的研究》,2013-2015
- 國家衛(wèi)生計(jì)生委醫(yī)政醫(yī)管局委托項(xiàng)目,《獻(xiàn)血法》修訂背景研究,2014-2016
- 北京協(xié)和醫(yī)學(xué)院《輸血醫(yī)學(xué)雙導(dǎo)師制教育改革項(xiàng)目》,2014-2016
- 北京協(xié)和醫(yī)學(xué)院,《輸血醫(yī)學(xué)研究生培養(yǎng)模式的研究》,2012-2015
- 四川省臍帶血干細(xì)胞庫,臍帶血安全有效性系列技術(shù)研究與應(yīng)用,2014-2017
- RhD免疫球蛋白的開發(fā)研究,新疆德源合作項(xiàng)目,2013-2016
- 國家衛(wèi)生計(jì)生委醫(yī)政醫(yī)管局委托項(xiàng)目,血站富余血漿用于血液制品生產(chǎn)可行性研究,2013-2016
- 輸血醫(yī)學(xué)研究生培養(yǎng)模式研究,2012-2016
著作
- 中國輸血不良反應(yīng)報(bào)告(2018–2020年),人民衛(wèi)生出版社. 2021.08(主編)
- 全血和成分血使用標(biāo)準(zhǔn)釋義,人民衛(wèi)生出版社. 2019.09(主編)
- 血液管理的法制化歷程,人民衛(wèi)生出版社. 2019.02(主編)
- 《中華輸血學(xué)》(第二版),人民衛(wèi)生出版社. 2022 (副主編)
- 《中華輸血學(xué)》(第一版),人民衛(wèi)生出版社. 2022 (副主編)
- Prenatal Diagnosis. Methods in molecular biology. Humana Press 2008-May-09;444: DOI: 10.1007/978-1-59745-066-9_16
- High-throughput Testing for the Determination of the Fetal Rh Factor in Maternal Plasma. 2008-NOV-21
代表性論文
- Kong Y, Tian X, He R, Zhong Liu*. The accumulation of exosome-associated microRNA-1246 and microRNA-150-3p in human red blood cell suspensions. J Transl Med. 2021;19(1).
- Yin Y, Li L, Gong L, Xu H, Liu Z*. Effects of riboflavin and ultraviolet light treatment on pathogen reduction and platelets [published online ahead of print, 2020 Aug 31. Transfusion. 2020;10.
- He R, Kong Y, Fang P, Li L, Shi H, Liu Z*. Integration of quantitative proteomics and metabolomics reveals tissue hypoxia mechanisms in an ischemic-hypoxic rat model. J Proteomics. 2020;228.
- Li L, Tong X, Chen H, Liu Z*, et al. Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donation. Transfusion. 2020;10.
- XiaomingZhou, Zhong Liu*, et al. Microfiltration-based sequential perfusion: A new approach for improved loading/ unloading of cryoprotectants. Sensors and Actuators: B. Chemical. 2020.
- Chen S, Xiao J, Song N, Xu H, Tian L, Liu Z*. A genetic polymorphism of IL17F rs763780 associated with anti-E production in the Han Chinese population. Transfus Apher Sci. 2020;102745.
- Li L, Zhang W, Hu Y, Tong X, … Wu Y, Liu Z*. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA. 2020;e2010044.
- Li L, Yang R, Wang J, Lv Q, … Wu Y, Liu Z*. Feasibility of a Pilot Program for COVID-19 Convalescent Plasma Collection in Wuhan, China. Transfusion. 2020.
- Kong Y, Cai C, Ling L, Zeng L, Wu M, Wu Y, Zhang W, Liu Z*. Successful treatment of a centenarian with coronavirus disease 2019 (COVID-19) using convalescent plasma. Transfus Apher Sci. 2020.
- Qiao J, He R, Yin Y, Tian L, Li L, Lian Z, Fang P, Liu Z*. rIL-35 prevents murine transfusion-related acute lung injury by inhibiting the activation of endothelial cells. Transfusion. 2020.
- Ma C, Wang S, Wang G, Wu Y, …, Yang L, Feng Y, Yu Y, Liu Z*, Wang D. Protein spectrum changes in exosomes after therapeutic plasma exchange in patients with neuromyelitis optica. J Clin Apher. 2020 Jun;35(3).
- Li L, Stansbury LG, Hess JR, Liu Z*. The first transfusions in China. Transfusion. 2020;60(5).
- Yu X, Wang Z, Shen Y, Liu Z, … etal. Population-based projections of blood supply and demand, China, 2017-2036. Bull World Health Organ. 2020 Jan 1;98(1).
- Li L, Ou S, Huang C, Zhou X, Ge H, …, Wu Y, Liu Z*. The prevalence of human T-cell leukemia virus in blood donors in China. Transfusion. 2019 Jul;59(7).
- Peng T, Zhao G, Wang L, Wu J, Cui H, Liang Y, Zhou R, Liu Z*, Wang Q. No impact of perioperative blood transfusion on prognosis after curative resection for hepatocellular carcinoma: a propensity score matching analysis. Clin Transl Oncol. 2018 Jun;20(6).
- Ou G, Xu H, Yu H, Liu X, Yang L, Ji X, Wang J, Liu Z*. The roles of HLA-DQB1 gene polymorphisms in hepatitis B virus infection. J Transl Med. 2018 Dec 18;16(1).
- Ou G, Liu X, Yang L, Yu H, Ji X, Liu F, Xu H, Qian L, Wang J, Liu Z*. Relationship between HLA-DPA1 mRNA expression and susceptibility to hepatitis B. J Viral Hepat. 2019.
- Rui He, Ling Li Yujie Kong, Li Tian, Xue Tian Peng Fang, Maohong Bian, Zhong Liu*. Preventing murine Transfusion-related acute lung injury by expansion of CD4+CD25+FoxP3+ Tregs using IL-2/anti-IL-2 complexes. Transfusion. 2019.
- Zhu L, Tong H, Wang S, Yu Y, Liu Z, Li C, Wang D. Effectiveness of a flow-based device using riboflavin photochemistry in damaging blood-borne viral nucleic acids. J Photochem Photobiol B. 2018 Jun.
- .Ling Li†,Tingting Han †,…Yanhua Li,Zhong Liu*. The current incidence, prevalence, and residual risk of hepatitis B viral infections among voluntary blood donors in China. Bmc Infectious Diseases, 2017, 17(1).
- .Kong Y, Tian X, Liu Z, Tian L. Identification of a novel missense mutation in A allele in a Chinese individual. Transfusion. 2017 Dec;57(12).
- Ling L, Ka Yi Li, Ke Yan, …Xiaohua Liang, Zhong Liu*, Yanyun Wu. The History and Challenges of Blood Donor Screening in China. Transfusion Medicine Reviews 2017, 31(2).
- Ya Wang, Yanyun Wu, Yongjun Chen, Changqing Li, Li Lu, Jim Aubuchon, Zhong Liu*. Journey towards safer and optimized blood banking practices in China from 1978 to 2015: National strategy and progress. Transfusion 2016, 56(12).
- Liu Y, Li C, Wang Y, Zhang Y, Wu B, Ke L, Xu M, Liu G, Liu Z*. Which is safer source plasma for manufacturing in China: apheresis plasma or recovered plasma? Transfusion. 2016 May;56(5).
- Li L, Xu T, Yang T, Zang L, … Wu Y, Liu Z*. Establishing a reentry procedure for human immunodeficiency virus screening-reactive donors in China. Transfusion , 2016, 56(1).
- Zhou X ,Zhang X,Zhang Y,Hong S,Li L,Liu Z*. Effects of lyophilization and rehydration on membrane surface antigens of human red blood cells. CryoLetters,2016,37(1).
- Wenjing Lu†, Yiping Chen†, Zhong Liu‡, Wenbo Tang§, Qiang Feng†, Jiashu Sun*†, and Xingyu Jiang*†. Quantitative Detection of MicroRNA in One Step via Next Generation Magnetic Relaxation Switch Sensing. ACS Nano, 2016 June 27.
- Yu X, Chen W, Liu Z, et al. Safety and current status of blood transfusion in China: an update. Lancet Haematol, 2016, 3(2).
- Yong-hua Yin, Chang-qing Li, Zhong Liu*. Blood donation in China: sustaining efforts and challenges in 3 achieving safety and availability. Transfusion,2015,55(10).
- Chen Q, Srivastava K, Liu Z, et al. Genotype frequency of human neutrophil antigen-3 polymorphisms in the Yi, Han, and Tibetan populations of China.[J]. Transfusion, 2015, 56(3).
- Ye L,Yu H, Li C, Hirsch ML, Zhang L, Samulski RJ,Li W, Liu Z*. Adeno-Associated Virus Vector Mediated Delivery of the HBV Genome Induces Chronic Hepatitis B Virus Infection and Liver Fibrosis in Mice. PLoS One. 2015 Jun15;10(6).
聯(lián)系方式
電話/傳真: 028-61648562